MOH — authorised 20 December 2002
- Marketing authorisation holder: BAXTER HLTHCARE
- Status: likely_approved
MOH authorised Extraneal on 20 December 2002
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 20 December 2002.
BAXTER HLTHCARE holds the Israeli marketing authorisation.